TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Actos Now for Prevention of Diabetes (ACT NOW)
Brief Summary: The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: ABT-335 + Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335, Other: Atorvastatin | Arm Label: Placebo + Atorvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Atorvastatin | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 + Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Atorvastatin | Intervention Type: OTHER; Name: Atorvastatin; Assigned to Arm(s): ABT-335 + Atorvastatin, Placebo + Atorvastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Actos Now for Prevention of Diabetes (ACT NOW)
Brief Summary: The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus


Options:
A: Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
D: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Actos Now for Prevention of Diabetes (ACT NOW)
Brief Summary: The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
D: Arm Label: Valsartan 160 mg + nateglinide 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg | Arm Label: Valsartan 160 mg + nateglinide placebo; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide placebo | Arm Label: Nateglinide 60 mg + valsartan placebo; Type: EXPERIMENTAL; Interventions: Drug: Nateglinide 60 mg + valsartan placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valsartan placebo + nateglinide placebo | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide 60 mg; Assigned to Arm(s): Valsartan 160 mg + nateglinide 60 mg | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide placebo; Assigned to Arm(s): Valsartan 160 mg + nateglinide placebo | Intervention Type: DRUG; Name: Nateglinide 60 mg + valsartan placebo; Assigned to Arm(s): Nateglinide 60 mg + valsartan placebo | Intervention Type: DRUG; Name: Valsartan placebo + nateglinide placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Actos Now for Prevention of Diabetes (ACT NOW)
Brief Summary: The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin
C: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-Based Cholesterol Assessment Trial
Brief Summary: The purpose of this trial is to find out if a special website might help people discover if they have high cholesterol and then enable them to manage their cholesterol more appropriately. The primary aim of this trial is to determine the effects on consumers' use of cholesterol lowering therapy of an online service that provides automated, individually tailored, advice about eligibility for cholesterol lowering treatment. The primary null hypothesis being tested is that the service will result in no change in the use of cholesterol lowering treatments by consumers that use the service.

The secondary aim of the trial is to see if it is possible to improve the cholesterol management of the friends or relatives of consumers that use the I-CAT service. The corresponding secondary null hypothesis being tested is that the I-CAT service will result in no change in the use of cholesterol lowering treatments by the friends or relatives of the consumers that use the service.


Options:
A: Arm Label: COACH; Type: ACTIVE_COMPARATOR; Interventions: Other: COACH | Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention for placebo | Intervention Type: OTHER; Name: COACH; Assigned to Arm(s): COACH | Intervention Type: OTHER; Name: No intervention for placebo; Assigned to Arm(s): Standard Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
C: Intervention Type: DEVICE; Name: Heart-to-Heart Decision Aid; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Internet-based tailored advice on cardiovascular risk; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.
Brief Summary: The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.


Options:
A: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Insulin infusion with a goal; Assigned to Arm(s): N/A
D: Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.
Brief Summary: The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.


Options:
A: Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
D: Arm Label: IgM-enriched Intravenous Immunoglobulins; Type: ACTIVE_COMPARATOR; Interventions: Drug: IgM-enriched Intravenous Immunoglobulins | Arm Label: Human Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: IgM-enriched Intravenous Immunoglobulins; Assigned to Arm(s): IgM-enriched Intravenous Immunoglobulins | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
B: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
C: Arm Label: AN69ST; Type: EXPERIMENTAL; Interventions: Device: AN69ST hemofilter | Arm Label: AN69; Type: ACTIVE_COMPARATOR; Interventions: Device: AN69 hemofilter | Intervention Type: DEVICE; Name: AN69ST hemofilter; Assigned to Arm(s): AN69ST | Intervention Type: DEVICE; Name: AN69 hemofilter; Assigned to Arm(s): AN69
D: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
B: Arm Label: Early RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Early RRT strategy | Arm Label: Delayed RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed RRT strategy | Intervention Type: PROCEDURE; Name: Early RRT strategy; Assigned to Arm(s): Early RRT strategy | Intervention Type: PROCEDURE; Name: Delayed RRT strategy; Assigned to Arm(s): Delayed RRT strategy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
D: Arm Label: Early renal replacement therapy; Type: EXPERIMENTAL; Interventions: Device: Dialysis with continuous renal replacement therapy, Device: Mechanical ventilator, Drug: Anti-Bacterial Agents, Drug: Vasopressors | Arm Label: Conventional renal replacement therapy; Type: PLACEBO_COMPARATOR; Interventions: Device: Dialysis with continuous renal replacement therapy, Device: Mechanical ventilator, Drug: Anti-Bacterial Agents, Drug: Vasopressors | Intervention Type: DEVICE; Name: Dialysis with continuous renal replacement therapy; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DEVICE; Name: Mechanical ventilator; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DRUG; Name: Anti-Bacterial Agents; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy | Intervention Type: DRUG; Name: Vasopressors; Assigned to Arm(s): Conventional renal replacement therapy, Early renal replacement therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Arm Label: heparin; Type: PLACEBO_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Arm Label: citrate regional anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): heparin | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): citrate regional anticoagulation, heparin
B: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock
C: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: D